
PubMed:8909998
Annnotations
GlyCosmos6-Glycan-Motif-Image
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 550-559 | Glycan_Motif | denotes | T-antigen | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00031MO |
T2 | 612-623 | Glycan_Motif | denotes | sialic acid | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY |
T3 | 820-829 | Glycan_Motif | denotes | T-antigen | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00031MO |
Glycosmos6-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 550-559 | http://www.glycoepitope.jp/epitopes/EP0020 | denotes | T-antigen |
T2 | 820-829 | http://www.glycoepitope.jp/epitopes/EP0020 | denotes | T-antigen |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-139 | Sentence | denotes | Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. |
TextSentencer_T2 | 140-355 | Sentence | denotes | We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleur et al., 1990, Cancer Res 50: |
TextSentencer_T3 | 356-560 | Sentence | denotes | 6334-43), in the presence of benzyl-N-acetyl-alpha-galactosaminide (GalNAc alpha-O-benzyl), which is a potential competitive inhibitor of the beta 1,3-galactosyltransferase that synthesizes the T-antigen. |
TextSentencer_T4 | 561-695 | Sentence | denotes | The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5 mM GalNAc alpha-O-benzyl. |
TextSentencer_T5 | 696-830 | Sentence | denotes | This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. |
TextSentencer_T6 | 831-939 | Sentence | denotes | The second observation was a decrease in the secretion of the mucins by GalNAc alpha-O-benzyl treated cells. |
TextSentencer_T7 | 940-1294 | Sentence | denotes | The decrease in mucin sialylation was achieved through the in situ beta-galactosylation of GalNAc alpha-O-benzyl into Gal beta 1-3GalNAc alpha-O-benzyl, which acts as a competitive substrate of Gal beta 1-3GalNAc alpha 2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAc alpha 2-3Gal beta 1-3GalNAc alpha-O-benzyl in treated cells. |
T1 | 0-139 | Sentence | denotes | Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. |
T2 | 140-355 | Sentence | denotes | We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleur et al., 1990, Cancer Res 50: |
T3 | 356-560 | Sentence | denotes | 6334-43), in the presence of benzyl-N-acetyl-alpha-galactosaminide (GalNAc alpha-O-benzyl), which is a potential competitive inhibitor of the beta 1,3-galactosyltransferase that synthesizes the T-antigen. |
T4 | 561-695 | Sentence | denotes | The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5 mM GalNAc alpha-O-benzyl. |
T5 | 696-830 | Sentence | denotes | This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. |
T6 | 831-939 | Sentence | denotes | The second observation was a decrease in the secretion of the mucins by GalNAc alpha-O-benzyl treated cells. |
T7 | 940-1294 | Sentence | denotes | The decrease in mucin sialylation was achieved through the in situ beta-galactosylation of GalNAc alpha-O-benzyl into Gal beta 1-3GalNAc alpha-O-benzyl, which acts as a competitive substrate of Gal beta 1-3GalNAc alpha 2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAc alpha 2-3Gal beta 1-3GalNAc alpha-O-benzyl in treated cells. |
GlyCosmos6-Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 550-559 | https://glytoucan.org/Structures/Glycans/G00031MO | denotes | T-antigen |
T2 | 612-623 | https://glytoucan.org/Structures/Glycans/G81533KY | denotes | sialic acid |
T3 | 820-829 | https://glytoucan.org/Structures/Glycans/G00031MO | denotes | T-antigen |
Glycosmos6-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 246-251 | http://purl.obolibrary.org/obo/MAT_0000526 | denotes | colon |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 246-261 | Disease | denotes | colon carcinoma | http://purl.obolibrary.org/obo/MONDO_0002032 |
T2 | 341-347 | Disease | denotes | Cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
Anatomy-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 246-251 | Body_part | denotes | colon | http://purl.obolibrary.org/obo/MAT_0000526 |
HP-phenotype
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 252-261 | Phenotype | denotes | carcinoma | HP:0030731 |
T2 | 341-347 | Phenotype | denotes | Cancer | HP:0002664 |
Glycan-GlyCosmos
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 424-430 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T2 | 673-679 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T3 | 903-909 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T4 | 1031-1037 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T5 | 1228-1233 | Glycan | denotes | NeuAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR |
GlyCosmos15-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 252-261 | Phenotype | denotes | carcinoma | HP:0030731 |
T2 | 341-347 | Phenotype | denotes | Cancer | HP:0002664 |
GlyCosmos15-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 246-251 | Body_part | denotes | colon | http://purl.obolibrary.org/obo/UBERON_0001155 |
T2 | 1198-1211 | Body_part | denotes | intracellular | http://purl.obolibrary.org/obo/GO_0005622 |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-139 | Sentence | denotes | Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. |
TextSentencer_T2 | 140-355 | Sentence | denotes | We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleur et al., 1990, Cancer Res 50: |
TextSentencer_T3 | 356-560 | Sentence | denotes | 6334-43), in the presence of benzyl-N-acetyl-alpha-galactosaminide (GalNAc alpha-O-benzyl), which is a potential competitive inhibitor of the beta 1,3-galactosyltransferase that synthesizes the T-antigen. |
TextSentencer_T4 | 561-695 | Sentence | denotes | The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5 mM GalNAc alpha-O-benzyl. |
TextSentencer_T5 | 696-830 | Sentence | denotes | This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. |
TextSentencer_T6 | 831-939 | Sentence | denotes | The second observation was a decrease in the secretion of the mucins by GalNAc alpha-O-benzyl treated cells. |
TextSentencer_T7 | 940-1294 | Sentence | denotes | The decrease in mucin sialylation was achieved through the in situ beta-galactosylation of GalNAc alpha-O-benzyl into Gal beta 1-3GalNAc alpha-O-benzyl, which acts as a competitive substrate of Gal beta 1-3GalNAc alpha 2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAc alpha 2-3Gal beta 1-3GalNAc alpha-O-benzyl in treated cells. |
T1 | 0-139 | Sentence | denotes | Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. |
T2 | 140-355 | Sentence | denotes | We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleur et al., 1990, Cancer Res 50: |
T3 | 356-560 | Sentence | denotes | 6334-43), in the presence of benzyl-N-acetyl-alpha-galactosaminide (GalNAc alpha-O-benzyl), which is a potential competitive inhibitor of the beta 1,3-galactosyltransferase that synthesizes the T-antigen. |
T4 | 561-695 | Sentence | denotes | The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5 mM GalNAc alpha-O-benzyl. |
T5 | 696-830 | Sentence | denotes | This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. |
T6 | 831-939 | Sentence | denotes | The second observation was a decrease in the secretion of the mucins by GalNAc alpha-O-benzyl treated cells. |
T7 | 940-1294 | Sentence | denotes | The decrease in mucin sialylation was achieved through the in situ beta-galactosylation of GalNAc alpha-O-benzyl into Gal beta 1-3GalNAc alpha-O-benzyl, which acts as a competitive substrate of Gal beta 1-3GalNAc alpha 2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAc alpha 2-3Gal beta 1-3GalNAc alpha-O-benzyl in treated cells. |
GlyCosmos15-Sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-139 | Sentence | denotes | Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. |
T2 | 140-355 | Sentence | denotes | We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleur et al., 1990, Cancer Res 50: |
T3 | 356-560 | Sentence | denotes | 6334-43), in the presence of benzyl-N-acetyl-alpha-galactosaminide (GalNAc alpha-O-benzyl), which is a potential competitive inhibitor of the beta 1,3-galactosyltransferase that synthesizes the T-antigen. |
T4 | 561-695 | Sentence | denotes | The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5 mM GalNAc alpha-O-benzyl. |
T5 | 696-830 | Sentence | denotes | This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. |
T6 | 831-939 | Sentence | denotes | The second observation was a decrease in the secretion of the mucins by GalNAc alpha-O-benzyl treated cells. |
T7 | 940-1294 | Sentence | denotes | The decrease in mucin sialylation was achieved through the in situ beta-galactosylation of GalNAc alpha-O-benzyl into Gal beta 1-3GalNAc alpha-O-benzyl, which acts as a competitive substrate of Gal beta 1-3GalNAc alpha 2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAc alpha 2-3Gal beta 1-3GalNAc alpha-O-benzyl in treated cells. |
GlyCosmos15-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 550-559 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | T-antigen | http://www.glycoepitope.jp/epitopes/EP0020 |
T2 | 820-829 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | T-antigen | http://www.glycoepitope.jp/epitopes/EP0020 |
GlyCosmos15-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 246-261 | Disease | denotes | colon carcinoma | MONDO:0002032 |
T2 | 341-347 | Disease | denotes | Cancer | MONDO:0004992 |
GlyCosmos15-NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 240-245 | OrganismTaxon | denotes | human | 9606 |
GlyCosmos15-FMA
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 246-251 | Body_part | denotes | colon | FMA:14543 |
GlyCosmos15-MAT
Id | Subject | Object | Predicate | Lexical cue | mat_id |
---|---|---|---|---|---|
T1 | 246-251 | Body_part | denotes | colon | http://purl.obolibrary.org/obo/MAT_0000526 |
GlyCosmos15-Glycan
Id | Subject | Object | Predicate | Lexical cue | image |
---|---|---|---|---|---|
T1 | 424-430 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T2 | 550-559 | Glycan | denotes | T-antigen | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00031MO |
T3 | 673-679 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T4 | 820-829 | Glycan | denotes | T-antigen | https://api.glycosmos.org/wurcs2image/latest/png/binary/G00031MO |
T5 | 903-909 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T6 | 1031-1037 | Glycan | denotes | GalNAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL |
T7 | 1228-1233 | Glycan | denotes | NeuAc | https://api.glycosmos.org/wurcs2image/latest/png/binary/G76685HR |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 240-245 | OrganismTaxon | denotes | human | 9606 |
GlyCosmos-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
---|---|---|---|---|---|
T1 | 550-559 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | T-antigen | http://www.glycoepitope.jp/epitopes/EP0020 |
T2 | 820-829 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | T-antigen | http://www.glycoepitope.jp/epitopes/EP0020 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 246-251 | Body_part | denotes | colon | http://purl.obolibrary.org/obo/UBERON_0001155 |
T2 | 1198-1211 | Body_part | denotes | intracellular | http://purl.obolibrary.org/obo/GO_0005622 |